

Heinz Zoller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8040163/publications.pdf>

Version: 2024-02-01

135
papers

4,782
citations

87843

38
h-index

114418

63
g-index

143
all docs

143
docs citations

143
times ranked

6149
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin-11 drives human and mouse alcohol-related liver disease. <i>Gut</i> , 2023, 72, 168-179.	6.1	13
2	Outcome of Budd-Chiari Syndrome Patients Treated With Direct Oral Anticoagulants: An Austrian Multicenter Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 978-987.e2.	2.4	12
3	Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. <i>Gut</i> , 2022, 71, 415-423.	6.1	28
4	Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management. <i>Bone</i> , 2022, 154, 116202.	1.4	40
5	The Need to Update Endpoints and Outcome Analysis in the Rapidly Changing Field of Liver Transplantation. <i>Transplantation</i> , 2022, 106, 938-949.	0.5	8
6	Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1009-1019.	1.8	20
7	A proteomic survival predictor for COVID-19 patients in intensive care. , 2022, 1, e0000007.		28
8	Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: A long-term follow-up study. <i>Annals of Hepatology</i> , 2022, 27, 100683.	0.6	4
9	Synonymous mutation in adenosine triphosphatase copper-transporting beta causes enhanced exon skipping in Wilson disease. <i>Hepatology Communications</i> , 2022, 6, 1611-1619.	2.0	6
10	Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide" results of a real world study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 144-154.	1.9	46
11	EASL Clinical Practice Guidelines on haemochromatosis. <i>Journal of Hepatology</i> , 2022, 77, 479-502.	1.8	49
12	Coronary atherosclerosis profile in patients with end-stage liver disease prior to liver transplantation due to alcoholic fatty liver: a coronary CTA study. <i>European Radiology</i> , 2021, 31, 494-503.	2.3	6
13	Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): Position paper on diagnosis, prognosis, and treatment by the <scp>MNGIE</scp> International Network. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 376-387.	1.7	47
14	Alpha-1 antitrypsin governs alcohol-related liver disease in mice and humans. <i>Gut</i> , 2021, 70, 585-594.	6.1	6
15	Performance of different Dixon-based methods for MR liver iron assessment in comparison to a biopsy-validated R2* relaxometry method. <i>European Radiology</i> , 2021, 31, 2252-2262.	2.3	25
16	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. <i>Journal of Hepatology</i> , 2021, 74, 801-810.	1.8	26
17	Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside" a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2256-2273.	1.1	61
18	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	1.8	149

#	ARTICLE	IF	CITATIONS
19	Neurodegeneration in Hepatic and Neurologic Wilson's Disease. <i>Hepatology</i> , 2021, 74, 1117-1120.	3.6	6
20	Systemic inflammation as fuel for acute liver injury in COVID-19. <i>Digestive and Liver Disease</i> , 2021, 53, 158-165.	0.4	63
21	Dual proteotoxic stress accelerates liver injury via activation of μ 62 α Nrf2. <i>Journal of Pathology</i> , 2021, 254, 80-91.	2.1	1
22	Advanced Microscopy for Liver and Gut Ultrastructural Pathology in Patients with MVID and PFIC Caused by MYO5B Mutations. <i>Journal of Clinical Medicine</i> , 2021, 10, 1901.	1.0	4
23	Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact. <i>World Journal of Gastroenterology</i> , 2021, 27, 2039-2053.	1.4	2
24	Newer formulations of intravenous iron: a review of their chemistry and key safety aspects "hypersensitivity, hypophosphatemia, and cardiovascular safety. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 757-769.	1.0	39
25	Static cold storage compared with normothermic machine perfusion of the liver and effect on ischaemic-type biliary lesions after transplantation: a propensity score-matched study. <i>British Journal of Surgery</i> , 2021, 108, 1082-1089.	0.1	43
26	DOP89 Effects of ferric derisomaltose and ferric carboxymaltose on hypophosphatemia in iron-deficiency anaemia due to Inflammatory Bowel Disease: A Phase IV randomised clinical trial. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S121-S121.	0.6	1
27	Direct Measurement of ATP7B Peptides Is Highly Effective in the Diagnosis of Wilson Disease. <i>Gastroenterology</i> , 2021, 160, 2367-2382.e1.	0.6	48
28	MRI-Based Iron Phenotyping and Patient Selection for Next-Generation Sequencing of Non-Homeostatic Iron Regulator Hemochromatosis Genes. <i>Hepatology</i> , 2021, 74, 2424-2435.	3.6	8
29	Expression of MICA in Zero Hour Biopsies Predicts Graft Survival After Liver Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 606146.	2.2	3
30	A time-resolved proteomic and prognostic map of COVID-19. <i>Cell Systems</i> , 2021, 12, 780-794.e7.	2.9	125
31	Using Infodemiology Metrics to Assess Public Interest in Liver Transplantation: Google Trends Analysis. <i>Journal of Medical Internet Research</i> , 2021, 23, e21656.	2.1	2
32	MR elastography in patients with suspected diffuse liver disease at 1.5T: Intraindividual comparison of gradient-recalled echo versus spin-echo echo-planar imaging sequences and investigation of potential confounding factors. <i>European Journal of Radiology</i> , 2021, 142, 109898.	1.2	7
33	Bone marker response to intravenous iron treatment - an in vitro model. , 2021, 59, .		0
34	Update on the Austrian epidemiology of Hepatitis D Virus (HDV). , 2021, 59, .		0
35	Reassessment of Relevance and Predictive Value of Parameters Indicating Early Graft Dysfunction in Liver Transplantation: AST Is a Weak, but Bilirubin and INR Strong Predictors of Mortality. <i>Frontiers in Surgery</i> , 2021, 8, 693288.	0.6	6
36	Afamin predicts the prevalence and incidence of nonalcoholic fatty liver disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, .	1.4	4

#	ARTICLE	IF	CITATIONS
37	Variants in <i>PCSK7</i> , <i>PNPLA3</i> and <i>TM6SF2</i> are risk factors for the development of cirrhosis in hereditary haemochromatosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 830-843.	1.9	9
38	Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis. <i>United European Gastroenterology Journal</i> , 2021, 9, 1119-1127.	1.6	20
39	Highly Elevated Plasma γ -Glutamyltransferase Elevations: A Trait Caused by γ -Glutamyltransferase 1 Transmembrane Mutations. <i>Hepatology</i> , 2020, 71, 1124-1127.	3.6	4
40	Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance. <i>Journal of Viral Hepatitis</i> , 2020, 27, 188-194.	1.0	20
41	Cloak and dagger ϵ -secondary hemophagocytic lymphohistiocytosis caused by intravenous autoinfection. <i>American Journal of Hematology</i> , 2020, 95, 330-332.	2.0	1
42	Liver stiffness by transient elastography accompanies illness severity in COVID-19. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000445.	1.1	20
43	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	1.8	282
44	Autologous stem cell transplantation following simultaneous liver and kidney transplantation in severe amyloid light chain amyloidosis associated with multiple myeloma: a case report. <i>Journal of Medical Case Reports</i> , 2020, 14, 201.	0.4	2
45	Fatty Liver Disease: Metabolic, Genetic, or Both?. <i>Hepatology Communications</i> , 2020, 4, 1239-1241.	2.0	0
46	Evaluation of liver iron overload with R2* relaxometry with versus without fat suppression: both are clinically accurate but there are differences. <i>European Radiology</i> , 2020, 30, 5826-5833.	2.3	5
47	Is Heterozygosity for the Alpha-1 Antitrypsin Risk Allele $\pi^M\pi^Z$ a Disease Modifier or Genetic Risk Factor?. <i>Gastroenterology</i> , 2020, 159, 433-434.	0.6	2
48	Anemia and iron deficiency in compensated and decompensated cirrhosis: Prevalence and impact on clinical outcomes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1619-1627.	1.4	12
49	Hypophosphatemia in children treated with ferric carboxymaltose. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2020, 109, 1491-1492.	0.7	11
50	Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 432.	3.8	162
51	Dietary lipids fuel GPX4-restricted enteritis resembling Crohn's disease. <i>Nature Communications</i> , 2020, 11, 1775.	5.8	143
52	Intravenous iron supplementation therapy. <i>Molecular Aspects of Medicine</i> , 2020, 75, 100862.	2.7	44
53	Reduced iron export associated with hepcidin resistance can explain the iron overload spectrum in ferroportin disease. <i>Liver International</i> , 2020, 40, 1941-1951.	1.9	10
54	Does gadoxetate disodium affect MRE measurements in the delayed hepatobiliary phase?. <i>European Radiology</i> , 2019, 29, 829-837.	2.3	7

#	ARTICLE	IF	CITATIONS
55	Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation. <i>Gastroenterology</i> , 2019, 157, 705-719.e18.	0.6	82
56	Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 397-406.	1.9	46
57	Reply. <i>Liver Transplantation</i> , 2019, 25, 344-345.	1.3	0
58	Reply. <i>Liver Transplantation</i> , 2019, 25, 1287-1288.	1.3	0
59	The dilemma to diagnose Wilson disease by genetic testing alone. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13147.	1.7	33
60	Iron Matryoshkaâ€”Haemochromatosis nested in Ferroportin Disease?. <i>Liver International</i> , 2019, 39, 1014-1015.	1.9	4
61	Management of patients with chronic hepatitis C failing repeated courses of interferonâ€free direct acting antiviral combination therapy. <i>GastroHep</i> , 2019, 1, 76-83.	0.3	5
62	P723 Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with iron isomaltoside or ferric carboxymaltose: results of a prospective cluster randomised cohort study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S482-S483.	0.6	0
63	HSD17B13 truncated variant is associated with a mild hepatic phenotype in Wilsonâ€™s Disease. <i>JHEP Reports</i> , 2019, 1, 2-8.	2.6	13
64	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , 2019, 10, 476.	2.2	134
65	P6149 Coronary computed tomographic angiography (CTA) for risk stratification in the diagnostic triage of patients undergoing liver transplantation (LT): A long-term outcome study. <i>European Heart Journal</i> , 2019, 40, .	1.0	0
66	Preoperative Assessment of Muscle Mass Using Computerized Tomography Scans to Predict Outcomes Following Orthotopic Liver Transplantation. <i>Transplantation</i> , 2019, 103, 2506-2514.	0.5	24
67	Stereotactic Radiofrequency Ablation of Hepatocellular Carcinoma: a Histopathological Study in Explanted Livers. <i>Hepatology</i> , 2019, 70, 840-850.	3.6	61
68	Age and Sex but Not ATP7B Genotype Effectively Influence the Clinical Phenotype of Wilson Disease. <i>Hepatology</i> , 2019, 69, 1464-1476.	3.6	110
69	Classical and intermediate monocytes scavenge non-transferrin-bound iron and damaged erythrocytes. <i>JCI Insight</i> , 2019, 4, .	2.3	42
70	OR13-3 Effects of Iron Isomaltoside versus Ferric Carboxymaltose on Hormonal Control of Phosphate Homeostasis: The PHOSPHARE-IDA04/05 Randomized Controlled Trials. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	2
71	Quantification of hepatic liver iron overload with laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS). , 2019, 57, .		0
72	Health Related Quality of Life and Healthcare Resource Utilization in chronic HCV patients under the Glecaprevir/Pibrentasvir Regimen: Interim-Analysis of the Austrian CONFIRMATION Study. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, .	0.2	0

#	ARTICLE	IF	CITATIONS
73	High pre-test likelihood for non-HFE mutations through full exome sequencing in patients with hepatic iron overload. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.2	0
74	Heterozygosity for the alpha ₁ -antitrypsin Z allele in cirrhosis is associated with more advanced disease. Liver Transplantation, 2018, 24, 744-751.	1.3	58
75	A rare case of Epstein-Barr virus-associated hepatosplenic smooth muscle tumors after kidney transplantation. Transplant Infectious Disease, 2018, 20, e12860.	0.7	3
76	Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation. Liver International, 2018, 38, 1188-1197.	1.9	8
77	Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment. Liver International, 2018, 38, 1028-1035.	1.9	51
78	Transferrin as a predictor of survival in cirrhosis. Liver Transplantation, 2018, 24, 343-351.	1.3	27
79	Con: Liver transplantation for expanded criteria malignant diseases. Liver Transplantation, 2018, 24, 104-111.	1.3	18
80	Liver transplantation for hilar cholangiocarcinoma (h-CCA): is it the right time?. Translational Gastroenterology and Hepatology, 2018, 3, 38-38.	1.5	6
81	Quantification of liver iron overload disease with laser ablation inductively coupled plasma mass spectrometry. BMC Medical Imaging, 2018, 18, 51.	1.4	10
82	Impact of patatin-like phospholipase domain containing rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension. Alimentary Pharmacology and Therapeutics, 2018, 48, 451-459.	1.9	26
83	Disease burden of hepatitis C in the Austrian state of Tyrol – Epidemiological data and model analysis to achieve elimination by 2030. PLoS ONE, 2018, 13, e0200750.	1.1	6
84	Liver disease in adults with alpha ₁ -antitrypsin deficiency. United European Gastroenterology Journal, 2018, 6, 710-718.	1.6	23
85	Monitoring Iron Overload: Relationship between R2* Relaxometry of the Liver and Serum Ferritin under Different Therapies. Journal of Clinical Imaging Science, 2018, 8, 40.	0.4	2
86	CCBE1 mutation causing sclerosing cholangitis: Expanding the spectrum of lymphedema-cholestasis syndrome. Hepatology, 2017, 66, 286-288.	3.6	6
87	R2*-relaxometry of the pancreas in patients with human hemochromatosis protein associated hereditary hemochromatosis. European Journal of Radiology, 2017, 89, 149-155.	1.2	7
88	Blood and Bone Loser. Gastroenterology, 2017, 152, e5-e6.	0.6	20
89	Iron-induced hypophosphatemia. Current Opinion in Nephrology and Hypertension, 2017, 26, 266-275.	1.0	121
90	3D Multiecho Dixon for the Evaluation of Hepatic Iron and Fat in a Clinical Setting. Journal of Magnetic Resonance Imaging, 2017, 46, 793-800.	1.9	40

#	ARTICLE	IF	CITATIONS
91	Letter: retreatment of patients with chronic hepatitis C who have failed interferon-free combination therapy with direct acting anti-virals. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 373-375.	1.9	4
92	Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth-III). <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 135-158.	1.0	111
93	Letter: inconsistency in reporting of hypophosphatemia after intravenous iron. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 641-643.	1.9	7
94	Hepatocellular carcinoma: when is liver transplantation oncologically futile?. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 63-63.	1.5	20
95	Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk. <i>PLoS ONE</i> , 2016, 11, e0167146.	1.1	68
96	DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting. <i>Transplant International</i> , 2016, 29, 999-1007.	0.8	73
97	Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy. <i>Liver International</i> , 2016, 36, 688-695.	1.9	38
98	Retrospective angiographic study to determine the effect of atherosclerotic stenoses of upstream arteries on the degree of atherosclerosis in distal vascular territories. <i>BMJ Open</i> , 2016, 6, e010704.	0.8	2
99	[⁶⁸ Ga]NODAGA-RGD – Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2005-2013.	3.3	38
100	Pathogenesis, Diagnosis and Treatment of Hemochromatosis. <i>Digestive Diseases</i> , 2016, 34, 364-373.	0.8	15
101	Indications for liver transplantation in adults. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 679-690.	1.0	39
102	Response to Successful liver transplantation for hepatocellular carcinoma following down-staging using sorafenib single therapy by Borentain et al.. <i>Liver International</i> , 2016, 36, 1394-1394.	1.9	0
103	Congenital secretory diarrhoea caused by activating germline mutations in <i>GUCY2C</i> . <i>Gut</i> , 2016, 65, 1306-1313.	6.1	74
104	Nonalcoholic fatty liver disease and hepatocellular carcinoma. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1151-1160.	1.5	143
105	EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH). <i>European Journal of Human Genetics</i> , 2016, 24, 479-495.	1.4	73
106	Tryptophan Breakdown in Patients with HCV Infection is Influenced by IL28B Polymorphism. <i>Pharmaceuticals</i> , 2015, 8, 337-350.	1.7	6
107	Impaired hepcidin expression in alpha-1-antitrypsin deficiency associated with iron overload and progressive liver disease. <i>Human Molecular Genetics</i> , 2015, 24, 6254-6263.	1.4	30
108	Should C282Y homozygotes with mild iron overload be treated?. <i>Journal of Hepatology</i> , 2015, 62, 510-511.	1.8	4

#	ARTICLE	IF	CITATIONS
109	R2* Relaxometry for the Quantification of Hepatic Iron Overload: Biopsy-Based Calibration and Comparison with the Literature. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2015, 187, 472-479.	0.7	59
110	Reduced sodium/proton exchanger NHE3 activity causes congenital sodium diarrhea. <i>Human Molecular Genetics</i> , 2015, 24, 6614-6623.	1.4	111
111	First experience with brentuximab vedotin in posttransplant lymphoproliferative disorder after liver transplantation: Complete remission followed by lethal sepsis. <i>Liver Transplantation</i> , 2014, 20, 1145-1148.	1.3	9
112	Iron metabolism in transplantation. <i>Transplant International</i> , 2014, 27, 1109-1117.	0.8	32
113	Effects of 24h working on-call on psychoneuroendocrine and oculomotor function: A randomized cross-over trial. <i>Psychoneuroendocrinology</i> , 2014, 47, 221-231.	1.3	22
114	Impact of D181V and A69T on the function of ferroportin as an iron export pump and hepcidin receptor. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 1406-1412.	1.8	18
115	Evaluation of liver fat in the presence of iron with MRI using T2* correction: a clinical approach. <i>European Radiology</i> , 2013, 23, 1643-1649.	2.3	19
116	Patatin-Like Phospholipase Domain-Containing Protein 3 rs738409-G in Recipients of Liver Transplants Is a Risk Factor for Graft Steatosis. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1667-1672.	2.4	81
117	Interferon-Alpha Therapy in Patients with Hepatitis C Virus Infection Increases Plasma Phenylalanine and the Phenylalanine to Tyrosine Ratio. <i>Journal of Interferon and Cytokine Research</i> , 2012, 32, 216-220.	0.5	28
118	Cystatin C is a strong predictor of survival in patients with cirrhosis: is a cystatin C-based MELD better?. <i>Liver International</i> , 2012, 32, 1211-1216.	1.9	25
119	Control of iron metabolism – Lessons from neonatal hemochromatosis. <i>Journal of Hepatology</i> , 2012, 56, 1226-1229.	1.8	30
120	Hepcidin is correlated to soluble hemojuvelin but not to increased GDF15 during pregnancy. <i>Blood Cells, Molecules, and Diseases</i> , 2012, 48, 233-237.	0.6	33
121	Identification of Mutations in SLC40A1 That Affect Ferroportin Function and Phenotype of Human Ferroportin Iron Overload. <i>Gastroenterology</i> , 2011, 140, 2056-2063.e1.	0.6	57
122	Saccadic latency in hepatic encephalopathy: a pilot study. <i>Metabolic Brain Disease</i> , 2010, 25, 285-295.	1.4	9
123	Clinical presentation and molecular pathophysiology of autosomal dominant hemochromatosis caused by a novel ferroportin mutation. <i>Hepatology</i> , 2010, 51, NA-NA.	3.6	24
124	Hepcidin messenger RNA expression in human lymphocytes. <i>Immunology</i> , 2010, 130, 217-230.	2.0	59
125	Ferroportin disease: A systematic meta-analysis of clinical and molecular findings. <i>Journal of Hepatology</i> , 2010, 53, 941-949.	1.8	121
126	Diagnosis of Hepatic Iron Overload. <i>Diagnostic Molecular Pathology</i> , 2009, 18, 53-60.	2.1	10

#	ARTICLE	IF	CITATIONS
127	Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency. <i>British Journal of Haematology</i> , 2009, 144, 789-793.	1.2	49
128	Autocrine formation of hepcidin induces iron retention in human monocytes. <i>Blood</i> , 2008, 111, 2392-2399.	0.6	255
129	Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor. <i>Human Pathology</i> , 2007, 38, 1057-1064.	1.1	37
130	CFTR gene mutations in pancreatitis: Frequency and clinical manifestations in an Austrian patient cohort. <i>Wiener Klinische Wochenschrift</i> , 2007, 119, 527-533.	1.0	12
131	Nanomedicines in the treatment of patients with hepatitis C co-infected with HIV ? focus on pegylated interferon-alpha. <i>International Journal of Nanomedicine</i> , 2006, 1, 399-409.	3.3	3
132	Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease. <i>Hepatology</i> , 2005, 42, 466-472.	3.6	54
133	Hemochromatosis: Genetic Testing and Clinical Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 945-958.	2.4	36
134	Iron supplementation in athletesâ€”first do no harm. <i>Nutrition</i> , 2004, 20, 615-619.	1.1	106
135	Duodenal cytochrome B and hephaestin expression in patients with iron deficiency and hemochromatosis. <i>Gastroenterology</i> , 2003, 125, 746-754.	0.6	50